Financial Performance - The company's operating revenue for 2021 was CNY 1,159,145,858.49, representing a 27.30% increase compared to CNY 910,535,393.22 in 2020[19]. - The net profit attributable to shareholders for 2021 was CNY 191,797,292.57, up 19.31% from CNY 160,756,584.19 in 2020[19]. - The net cash flow from operating activities reached CNY 224,441,512.69, an increase of 17.79% compared to CNY 190,551,383.85 in 2020[19]. - The total assets at the end of 2021 were CNY 1,465,507,510.72, reflecting an 18.91% increase from CNY 1,232,498,314.95 at the end of 2020[19]. - The basic earnings per share for 2021 was CNY 2.0491, a 19.31% increase from CNY 1.7175 in 2020[19]. - The company reported a weighted average return on equity of 18.66% for 2021, slightly down from 18.91% in 2020[19]. - The net profit after deducting non-recurring gains and losses was CNY 173,711,247.27, which is a 27.69% increase from CNY 136,040,893.94 in 2020[19]. - The company recorded quarterly revenues of CNY 264,095,393.20, CNY 331,960,010.35, CNY 315,605,098.24, and CNY 247,485,356.70 for Q1, Q2, Q3, and Q4 respectively[22]. - The company received government subsidies amounting to CNY 16,891,462.66 in 2021, compared to CNY 16,321,961.58 in 2020[25]. - The total equity attributable to shareholders at the end of 2021 was CNY 1,117,772,193.79, a 19.96% increase from CNY 931,782,994.87 at the end of 2020[19]. Risk Management - The company emphasizes the importance of risk awareness regarding forward-looking statements related to strategic goals and operational plans[4]. - The report includes a section on potential risks the company may face in future operations, which investors are encouraged to review[4]. - The company is facing uncertainties due to the ongoing COVID-19 pandemic, which has impacted production and operations[98]. - The company will strengthen its supply chain by deepening strategic partnerships with suppliers to mitigate the impact of raw material price fluctuations[98]. Product and Market Development - The company operates in the "C29 Rubber and Plastic Products Industry," which is supported by national policies promoting high-end manufacturing and precision mold design[30]. - The precision injection mold and injection parts are widely used in electronics, automotive, and home appliance sectors, indicating a diversified market presence[31]. - The health product market, particularly air purifiers, is expected to grow significantly due to rising health awareness and the impact of the COVID-19 pandemic[32]. - The company has established a global production base with facilities in Xiamen, Shanghai, Tianjin, Quanzhou, Germany, and Malaysia, enhancing its competitive edge[31]. - The company has expanded its business model to include "mold-integration," providing a one-stop solution for clients in various industries[35]. - The company’s product line includes precision injection molds, injection parts, and health products, catering to diverse customer needs[35]. - The company is positioned to benefit from the increasing demand for lightweight materials in the automotive sector, which is expected to enhance the market for plastic molds[32]. - The company has diversified its product structure and expanded into various application markets, including electronics, automotive, home, and health appliances, effectively mitigating risks associated with market fluctuations[55]. Research and Development - Research and development investment reached CNY 43.85 million, an increase of 34.47% year-on-year, to maintain technological leadership[62]. - The number of R&D personnel increased to 241, a rise of 13.15% from 213 in 2020, with R&D personnel now accounting for 13.59% of the total workforce[76]. - The company has accumulated 370 authorized patents, including 20 invention patents, which support its long-term competitive advantage in precision injection mold design and processing[54]. - The company has invested in advanced manufacturing equipment, including five-axis CNC machining centers and automated optical inspection systems, enhancing production efficiency and quality control[55]. Corporate Governance - The company maintains complete independence from its controlling shareholders in terms of assets, personnel, finance, organization, and business operations[108]. - The company has established an independent financial department with a standardized accounting system and independent bank accounts, ensuring no shared accounts with controlling shareholders[109]. - The board of directors and senior management are elected and appointed according to legal regulations, ensuring no undue influence from shareholders[109]. - The company has a governance structure that complies with legal and regulatory requirements, with no significant discrepancies[107]. - The company has a diverse leadership team with extensive experience in the industry, enhancing its operational capabilities[113]. Environmental Responsibility - The company is committed to continuous improvement in environmental management practices[149]. - The company actively participates in social welfare, donating 60,000 yuan to the Xiamen Disabled Persons Welfare Foundation[154]. - The company has implemented measures to reduce carbon emissions, although specific details were not disclosed[156]. - The company maintains compliance with environmental standards, including wastewater and noise emissions, meeting various national regulations[156]. - The company has no significant environmental risks as it operates in a non-polluting industry[149]. Employee Management - The company emphasizes a performance-oriented compensation system to encourage employee efficiency and contributions[135]. - The company has established a comprehensive talent training mechanism, including entry training, on-the-job training, and transfer training[136]. - The total remuneration for directors, supervisors, and senior management in 2021 amounted to 3.87 million CNY[122]. - The company has a total of 1,192 production personnel, 67 sales personnel, 241 technical personnel, 59 financial personnel, and 215 administrative personnel[134]. Shareholder Returns - The company plans to distribute a cash dividend of 6.00 CNY per 10 shares to all shareholders, based on a total of 124,800,000 shares[4]. - The cash dividend distribution will not adversely affect the company's liquidity or operational capabilities[140]. - The company has not proposed any stock bonus or capital increase through capital reserves for the year[140]. - The total distributable profit for the year is RMB 446,587,772.74[140]. Strategic Planning - The company aims to enhance customer value and create high-quality products and services, focusing on technology innovation and rapid response[94]. - The company plans to develop a modern manufacturing system integrating the entire industry chain from precision injection molds to health products[94]. - The company will continue to expand its marketing service network in Europe, North America, and Southeast Asia to better serve international clients[96]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million RMB allocated for potential deals[119].
唯科科技(301196) - 2021 Q4 - 年度财报